Sera Prognostics (Sera Prognostics) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics COGS-to-Revenue?

Sera Prognostics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.02 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

Sera Prognostics's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sera Prognostics's Gross Margin % for the three months ended in Mar. 2024 was %.

Sera Prognostics COGS-to-Revenue Historical Data

The historical data trend for Sera Prognostics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics COGS-to-Revenue Chart

Sera Prognostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.50

0.44

0.45

0.72

0.69

Sera Prognostics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial													0.62	0.65	1.05	0.59	-

Sera Prognostics COGS-to-Revenue Calculation

Sera Prognostics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.21	/	0.306
	=	0.69

Sera Prognostics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.017	/	0
	=

Sera Prognostics (NAS:SERA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sera Prognostics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.017 / 0
	=	%

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Sera Prognostics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sera Prognostics (Sera Prognostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sera Prognostics Inc (NAS:SERA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109

Website

https://www.seraprognostics.com

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.

Executives

John J. Boniface	officer: Chief Scientific Officer	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson	officer: General Counsel	320 WAKARA WAY, SALT LAKE CITY UT 84108
Austin Aerts	officer: Chief Financial Officer	2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison	officer: Chief Information Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley	officer: Chief Medical Officer	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence	director	C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Zhenya Lindgardt	director	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney	officer: Chief Data Officer	2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Blue Ox Healthcare Partners, Llc	10 percent owner	239 DAWSON ROAD, HILLSIDE NY 12529
Nichole L. Martin	officer: VP OF Q/R & HIPPA PRIV. OFF	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Marcus Dean Wilson	director	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Joshua Phillips	director	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Nadia Altomare	officer: Chief Commercial Officer	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109